Clorgyline hydrochloride (Standard)

[1]. Knoll J. The possible mechanisms of action of (-)deprenyl in Parkinson's disease. J Neural Transm. 1978;43(3-4):177-98. [Content Brief]

[2]. Zhao H, et al. Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC medical genomics. 2009 Aug 20;2:55.

[3]. Garcia-Miralles M, et al. Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease. Experimental neurology. 2016 Apr;278:4-10.

[4]. Ross RJ, et al. The effect of clorgyline on noradrenergic function. Psychopharmacology. 1985;85(2):227-30.

[5]. Seymour CB, et al. Monoamine oxidase inhibitors l-deprenyl and clorgyline protect nonmalignant human cells from ionising radiation and chemotherapy toxicity. British journal of cancer. 2003 Nov 17;89(10):1979-86.

[6]. Tamarkin L, et al. Effect of clorgyline (a MAO type A inhibitor) on locomotor activity in the Syrian hamster. The American journal of physiology. 1983 Aug;245(2):R215-21.

[7]. Feldman JM, et al. Effect of the monoamine oxidase inhibitors clorgyline and pargyline on the hyperphagia of obese mice. Behavioural brain research. 1988 Jul;29(1-2):147-58.

[8]. Campbell IC, et al. The effects of chronic regimens of clorgyline and pargyline on monoamine metabolism in the rat brain. J Neurochem. 1979 Jan;32(1):49-55.

[9]. Green AR, et al. Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. British journal of pharmacology. 1975 Nov;55(3):415-22.